Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
0.2238
+0.0002 (0.09%)
At close: Jun 6, 2025, 4:00 PM
0.2229
-0.0009 (-0.40%)
After-hours: Jun 6, 2025, 7:19 PM EDT
Vor Biopharma Stock Forecast
VOR's stock price has decreased by -82.92% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Vor Biopharma stock ranges from a low of $3.00 to a high of $14. The average analyst price target of $7.20 forecasts a 3,117.16% increase in the stock price over the next year.
Price Target: $7.20 (+3,117.16%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Vor Biopharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 5 | 5 | 5 | 5 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy → Hold Downgrades $6 | Buy → Hold | Downgrades | $6 | +2,580.97% | May 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 9, 2025 |
| Oppenheimer | Oppenheimer | Buy Reiterates $8 | Buy | Reiterates | $8 | +3,474.62% | Mar 21, 2025 |
| Stifel | Stifel | Strong Buy Maintains $12 → $5 | Strong Buy | Maintains | $12 → $5 | +2,134.14% | Mar 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $13 | Strong Buy | Maintains | $18 → $13 | +5,708.76% | Mar 21, 2025 |
Financial Forecast
Revenue This Year
n/a
from 258.19M
Revenue Next Year
n/a
EPS This Year
-0.65
from -1.70
EPS Next Year
-0.66
from -0.65
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 102.2M | ||
| Avg | n/a | n/a | 26.5M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.39 | -0.16 | -0.63 | ||
| Avg | -0.65 | -0.66 | -0.90 | ||
| Low | -0.93 | -1.59 | -1.24 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.